CALCIVIS secures £4.5m Series A investment led by Archangels to fund US expansion.
The Edinburgh medical device firm secured backing from Archangels and the Scottish Investment Bank to prepare for its American market entry.
CALCIVIS is a medical devices company that develops diagnostic tools for managing tooth decay and supporting preventive dentistry. The firm is based in Edinburgh.
CALCIVIS has secured £4.5m in a Series A equity funding round led by Archangels with backing from the Scottish Investment Bank. The capital will support corporate development as the firm awaits US regulatory approval for its imaging system and prepares for entry into the American market.
The financing follows positive results from clinical evaluations assessing active dental demineralisation. The company plans to launch its diagnostic device in the US in 2020, subject to clearance from federal regulators.
From the founder
"We are delighted by the continuing commitment of our existing investors in this financing. This new investment allows us to continue to execute our strategy as we anticipate PMA approval for our CALCIVIS Imaging System later this year from FDA. We remain very confident in the potential of this new approach to preventive dentistry in the US, when it is launched in the world’s largest dentistry market in 2020. This optimism has been reinforced by our experience in the UK, where the CALCIVIS Imaging System has been shown to provide reliable, visualisation of demineralisation enabling bespoke, evidence-based preventive treatment for dental caries patients."
Adam Christie
CEO at CALCIVIS
Investor perspective
"Our investment in CALCIVIS is driven by our belief that the CALCIVIS Imaging System will prove to be a catalyst for the wide-spread adoption of preventive dentistry, bringing significant benefits both to patients and dental practitioners. We are confident that PMA approval of this system will add shareholder value and we look forward to Adam and the CALCIVIS team achieving this major breakthrough, which would not only be game-changing for dentistry but an amazing achievement for the company."
Sarah Hardy
Director and Head of New Investments, Archangels
Use of funds
- 01Expand into international markets
